Hexarelin

Mechanism of action

Agonist of the GHS-R1a receptor (ghrelin receptor) expressed at the hypothalamic and pituitary levels: it increases the release of GH (in a pulsatile manner) and may variably increase IGF-1 through the GH–IGF-1 axis. GHS-R1a activation may also influence appetite, glucose homeostasis, and the secretion of other hormones (e.g. prolactin and cortisol in some studies). It is distinct from GHRH analogues: GHS act through partially independent pathways and may show synergy with GHRH in experimental protocols.

Supported benefits

• Acute increase in GH secretion (dose-dependent response in controlled studies) (strong)
• Increase in IGF-1 in some protocols (variable; depends on dose, duration, and population) (moderate)
• Possible effects on body composition (lean/fat mass) in experimental settings, with inconclusive results and often confounded by water retention (limited)
• Possible cardiovascular effects (e.g. myocardial function) observed mainly in preclinical models and small clinical studies (emerging)

Safety & side effects

• Increased appetite
• Water retention, peripheral edema, possible rapid weight gain
• Paresthesias or carpal tunnel-like symptoms (if the GH/IGF-1 axis is significantly stimulated)
• Headache, flushing, dizziness (reported in some protocols)
• Possible alterations in blood glucose and insulin sensitivity (direction and magnitude vary; greater risk in those predisposed to metabolic disorders)
• Possible increase in prolactin and/or cortisol in some individuals
• Injection-site reactions (pain, redness, infection) if administered parenterally

FAQ

Is Hexarelin the same thing as GH?

No. Hexarelin is a secretagogue: it stimulates the endogenous release of GH through ghrelin receptors. GH is the hormone administered directly. The effects, pharmacokinetics, and risks may differ.

Does it really increase IGF-1?

In some studies IGF-1 increases, but the response is variable and depends on dose, duration, nutritional status, age, and individual sensitivity of the GH–IGF-1 axis.

Is it useful for increasing muscle mass and performance?

The acute increase in GH is well documented, but there is no solid and consistent evidence that this translates into significant performance improvements in healthy individuals. Part of the perceived changes may depend on water retention.

What are the main risks?

Water retention/edema, blood glucose alterations, possible changes in prolactin/cortisol, symptoms from excessive GH/IGF-1 signaling, and infectious/contamination risks linked to unregulated preparations.

Can it be detected in anti-doping testing?

GH secretagogues are prohibited in regulated sport. Detection methods and windows depend on the laboratory, biological matrix, and protocols; the risk of an anti-doping violation is real.